STOCK TITAN

Centogene N.V. Common Shares - CNTG STOCK NEWS

Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.

Centogene N.V. (Nasdaq: CNTG) delivers cutting-edge solutions in genetic diagnostics and multiomic analysis for rare diseases. This news hub provides investors and healthcare professionals with essential updates on the company's scientific advancements, financial developments, and strategic partnerships.

Access authoritative information about CNTG's diagnostic innovations, pharmaceutical collaborations, and biodatabank expansions. Our curated news collection features official press releases covering clinical study results, regulatory milestones, and business performance updates. Track the company's progress in translating genetic insights into precision medicine solutions.

Key updates include announcements about diagnostic test approvals, research publications, partnership agreements with biopharma leaders, and financial disclosures. All content is verified from primary sources to ensure accuracy and timeliness. The repository serves as a strategic resource for understanding Centogene's role in advancing rare disease research and treatment development.

Bookmark this page for streamlined access to Centogene's latest developments. Check back regularly to stay informed about critical updates affecting the company's position in genetic medicine and healthcare innovation.

Rhea-AI Summary

Centogene N.V. announced an extension of the Rostock International Parkinson's Disease (ROPAD) Study, aimed at enhancing understanding of Parkinson's disease (PD) genetics. Following the testing of over 12,500 participants, the study will expand its recruitment efforts at 48 sites across 10 countries. The study focuses on genetic variations in the LRRK2 gene, with potential eligibility for patients in ongoing therapeutic clinical studies. The collaboration with Denali Therapeutics aims to accelerate drug discovery for PD, which affects over 10 million people globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
none
-
Rhea-AI Summary

Premier Research and Centogene have entered a strategic partnership aimed at enhancing clinical trials for rare diseases. The collaboration focuses on better patient identification, recruitment, and enrollment, with the goal of increasing trial success rates. Centogene's Biodatabank and advanced multiomic laboratories will provide essential data-driven insights, supporting the design and execution of rare disease studies. With over 350 million patients affected globally and 95% lacking treatments, this partnership seeks to fast-track clinical outcomes and drug development in a historically challenging field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
partnership clinical trial
-
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) has announced participation in the 41st Annual J.P. Morgan Healthcare Meeting from January 9-12, 2023, in San Francisco. The company aims to engage with potential partners and investors about its strategic developments in precision medicine, particularly in rare and neurodegenerative diseases. Additionally, Centogene will attend the Fierce JPM Week on January 10, 2023. The management team, including CEO Kim Stratton, will be present to discuss initiatives aimed at accelerating drug discovery and development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
none
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) reported unaudited financial results for Q2 and H1 2022, showing a 21.6% increase in revenues to €11.2 million. The Diagnostics segment saw an 18.3% rise to €7.5 million, while the Pharma segment increased 29% to €3.7 million. Despite a net loss of €11.9 million in Q2, the loss improved by 11.9% YoY. Total revenues for H1 were €21.4 million, up 12.6%. The company anticipates 2022 revenue growth between 9% to 13%, reaching €46.5 to €48.2 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.8%
Tags
-
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) has been notified by Nasdaq that it has not met the minimum bid price requirement of $1.00 for 30 consecutive business days. The company has until June 12, 2023, to regain compliance, during which its shares will continue to trade on Nasdaq. If the bid price closes at or above $1.00 for 10 consecutive days before this deadline, the compliance issue will be resolved. The company is evaluating options to address this deficiency but remains committed to its mission in the rare and neurodegenerative diseases sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.8%
Tags
none
-
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) announces its conference schedule for December 2022, highlighting participation in the 4th Annual Gene Therapy for Neurological Disorders Meeting from December 5-8 in Boston and the 67th Annual Meeting of the Japan Society of Human Genetics from December 14-17 in Yokohama. The company invites attendees to schedule one-on-one meetings with its Pharma and CRO business development team. Centogene focuses on life science solutions for rare and neurodegenerative diseases, leveraging its Biodatabank for enhanced diagnostics and drug discovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
conferences
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) announced its conference schedule for November 2022, highlighting participation in events in the U.S. and Spain to foster collaboration in rare and neurodegenerative diseases. Key events include the World Orphan Drug Congress (WODC) Europe from November 14-17, 2022 in Barcelona, and the NSGC Annual Conference from November 16-20, 2022 in Nashville, TN. Centogene invites attendees to arrange one-on-one meetings, aiming to enhance partnerships and dialogue in precision medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
conferences
-
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) has launched its Biodata Network, a suite of data-driven solutions aimed at enhancing drug discovery for rare and neurodegenerative diseases. The company partnered with BC Platforms to provide access to a comprehensive dataset, featuring 80,000 genetic sequences and expanding the genomic data available by 20%. This initiative supports biopharma companies with customized Biodata Licenses and Insight Reports, aiming to accelerate therapeutic development. Centogene's Biodatabank comprises nearly 700,000 patients from over 120 countries, emphasizing patient privacy and compliance with regulations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
none
-
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) has announced its participation in two major events in October 2022, focusing on rare and neurodegenerative diseases. The company will attend the ESGCT Annual Congress in Edinburgh from October 11-14, 2022, offering one-on-one meetings. Following that, it will participate in BIO-Europe in Leipzig from October 24-26, 2022, featuring a digital presentation by CEO Kim Stratton. Partners are encouraged to schedule meetings to explore collaborations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
conferences
Rhea-AI Summary

Centogene N.V. (Nasdaq: CNTG) has achieved a significant milestone in the Rostock International Parkinson's Disease (ROPAD) Study, enrolling and genetically testing 12,500 participants globally. This study is the largest of its kind, aiming to understand genetics in Parkinson's disease (PD) through over 120 study sites worldwide. The company collaborates with Denali Therapeutics to develop a first-in-class Parkinson’s Disease Panel, screening for mutations in the LRRK2 gene. Participants with these mutations may qualify for future clinical studies to explore new therapeutic avenues for PD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
Centogene N.V. Common Shares

Nasdaq:CNTG

CNTG Rankings

CNTG Stock Data

9.43M
29.00M
4.57%
66.89%
0.28%
Diagnostics & Research
Healthcare
Link
Germany
Rostock